Keros Therapeutics (KROS) FCF Margin (2019 - 2025)
Keros Therapeutics (KROS) reported FCF Margin of 4485.27% for Q4 2025, down 1359885.0% on a YoY basis from N/an in Q4 2024, and down 34752.71% quarter-over-quarter from 12.94% in Q3 2025.
Keros Therapeutics (KROS) FCF Margin (2019 - 2025) Analysis & Trends
Keros Therapeutics has reported FCF Margin for 6 years, with the latest figure at 4485.27% in Q4 2025.
- For the quarter ending Q4 2025, FCF Margin fell 1359885.0% year-over-year to 4485.27%; the trailing twelve-month figure through Dec 2025 stood at 44.01% (down 13562265.0% YoY), and the FY2025 full-year result was 44.05%, changed N/A from the prior year.
- FCF Margin for Q4 2025 stood at 4485.27%, down from 12.94% in the prior quarter.
- The five-year high for FCF Margin was 9113.58% in Q4 2024, with the low at 408362.5% in Q3 2023.
- Historically, FCF Margin has averaged 40793.06% across 5 years, with a median of 160.02% in 2025.
- Annual changes were most pronounced in 2024 — FCF Margin soared 40010013 bps — and 2025, when it sank 1359885 bps.
- Keros Therapeutics' FCF Margin stood at 110.19% in 2021, then soared by 92 bps to 8.41% in 2022, then plunged by 216048 bps to 18180.42% in 2023, then jumped by 150 bps to 9113.58% in 2024, then sank by 149 bps to 4485.27% in 2025.
- The last three FCF Margin figures came in at 4485.27% (Q4 2025), 12.94% (Q3 2025), and 160.02% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -3.98% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 43.35% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Keros Therapeutics | 399.01 Mn | 111.61 Mn | - | -4,485.27% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -4,485.27% |
| Sep 30, 2025 | 12.94% |
| Jun 30, 2025 | -160.02% |
| Mar 31, 2025 | 76.03% |
| Dec 31, 2024 | 9,113.58% |
| Sep 30, 2024 | -8,262.37% |
| Dec 31, 2023 | -18,180.42% |
| Sep 30, 2023 | -408,362.50% |
| Mar 31, 2022 | -8.41% |
| Dec 31, 2021 | -110.19% |
| Jun 30, 2021 | -18,357.00% |
| Dec 31, 2019 | -220.64% |
| Sep 30, 2019 | -121.48% |
| Jun 30, 2019 | -208.12% |
| Mar 31, 2019 | -100.52% |